13908-45-7

Basic information

• Product Name: 3-{[(2-chloroethyl)carbamoyl]amino}benzoic acid
• Synonyms: 3-({[(2-chloroethyl)amino]carbonyl}amino)benzoic acid; benzoic acid, 3-[[[(2-chloroethyl)amino]carbonyl]amino]-
• CAS NO: 13908-45-7
• Molecular Formula: C₁₀H₁₁ClN₂O₃
• Molecular Weight: 242.6589
• Mol File: 13908-45-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 413.7°C at 760 mmHg
• Flash Point: 204°C
• Density: 1.412g/cm³
• Vapor Pressure: 1.39E-07mmHg at 25°C
• Refractive Index: 1.622
• CAS DataBase Reference: 3-{[(2-chloroethyl)carbamoyl]amino}benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{[(2-chloroethyl)carbamoyl]amino}benzoic acid(13908-45-7)
• EPA Substance Registry System: 3-{[(2-chloroethyl)carbamoyl]amino}benzoic acid(13908-45-7)

Safety Data

• Hazardous Substances Data: 13908-45-7(Hazardous Substances Data)

Upstream product

• 1943-83-5 2-chloroethyl isothiocyanate 
• 99-05-8 meta-aminobenzoic acid 

Downstream Products

• 13909-24-5 C₁₀H₁₀ClN₃O₄ 

Relevant articles and documents

N-Phenyl-N′-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents. Part 3: Role of carbonyl groups in the covalent binding to the colchicine-binding site

In the course of the development of N-phenyl-N′-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents, we investigated the effect of carbonylated substituting chains of the aromatic ring of CEU on their covalent binding to the colchicine-binding site (C-BS). In this study, we found that CEU, 5e, 5f, 8e, and 8f substituted by either a methyl ester or a methyl ketyl group at the ω-position exhibited a significant antiproliferative activity on HT-29, M21, and MCF-7 tumor cells. SDS-PAGE assays and cell cycle analysis confirmed that 5e, 5f, 8e, and 8f covalently bind to the C-BS and arrest the cell division in G2/M phase. Surprisingly, the presence of ω-carboxyl, ω-ethyl esters or ω-amides decreased significantly both the antiproliferative activity and the specificity toward β-tubulin.

HALOETHYL UREA COMPOUNDS AND THE USE THEREOF TO ATTENUATE, INHIBIT OR PREVENT CANCER CELL MIGRATION

The present invention provides haloethyl urea compounds as described in Formula (I) and their use as therapeutic agent in the attenuation, inhibition, or prevention of cancer cell migration and cancer cell proliferation.